The last 3 years brought forth new terminologies, such as those included in the WHO 2022 classification; for example, “multi-glandular” is now used instead of the prior “hyperplasia”, there are new definitions for carcinomas and atypical tumors (previously described as “adenomas”), including the distinct subgroup of “parafibromin-deficient neoplasms”, in association with the increasing importance of genetics, immunohistochemistry, and molecular biology assessments in parathyroid tumors [88]. This evidence concerns the gene CDC73 and adenoma.